Article
CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Clinical pharmacology and therapeutics - 1 Feb 2014
Province M A, Goetz M P, Brauch H, Flockhart D A, Hebert J M, Whaley R, Suman V J, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman W G, Lee M-T M, Ambrosone C B, Beckmann M W, Choi J-Y, Dieudonné A-S, Fasching P A, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan L B, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen A T, Park B-W, Purdie C A, Quinlan P, Renner W, Schmidt M, Schwab M, Shin J-G, Stingl J C, Wegman P, Wingren S, Wu A H B, Ziv E, Zirpoli G, Thompson A M, Jordan V C, Nakamura Y, Altman R B, Ames M M, Weinshilboum R M, Eichelbaum M, Ingle J N, Klein T E
Abstract excerpt
The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
